TrialAdvances in therapy2025

A Randomized Phase I Trial Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eclitasertib, a RIPK1 Inhibitor, in Healthy Participants.

Christine Farenc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.